New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...

Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC: Berlin Friday, November 21, 2025, 11:00 Hrs [IST] Following ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme's ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Phase 3 Study initiating in First Quarter of 2026Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food ...

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration ...

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

Immunotherapy—could that be an option for me, doctor?” is a question frequently asked by patients with colorectal cancer. The ...